MORE VIDEOS
Explore more

Latest videos

Sean’s Story: Amyloidosis
Sean’s Story: Amyloidosis administrator 0 Views • 1 month ago

In this video, Sean Riley from New Hampshire shares his health journey with amyloidosis, a rare genetic condition caused by mutations in certain genes that lead to the abnormal production of amyloid proteins. These proteins misfold and deposit in tissues and organs, disrupting their normal function. Sean is a speaker and advocate for the Amyloidosis Speaker Bureau and explains the disease burden of ATTR‐CM from a patient perspective and the value of treatments for amyloidosis to improve the quality of life for patients with this hereditary condition.

This patient perspective video was developed for the AMCP Nexus 2024 grant-funded session, D3 Rare Disease Spotlight: Transthyretin Amyloidosis Cardiomyopathy (ATTR‐CM) Disease Burden, Unmet Needs, and Treatment Advances.

View Session: https://amcplearn.org/content/....rare-disease-spotlig

View other patient stories and disease state resources to inform health care decision-making at: https://www.amcp.org/patient-j....ourneys-shaping-heal

Cardiac Amyloidosis: Navigating Diagnostic Challenges and Therapeutic Horizons in 2025
Cardiac Amyloidosis: Navigating Diagnostic Challenges and Therapeutic Horizons in 2025 administrator 0 Views • 1 month ago

Cardiac amyloidosis is a condition affecting over 300,000 people globally with rogue proteins invading the heart. This condition has long been a diagnostic puzzle but hope is on the horizon!

In case you missed it, the FDA has approved BridgeBio’s (BBIO) Acoramidis, also known as Attruby, a transthyretin stabilizer revolutionizing care for ATTR-CM. And that’s not all!

Vutrisiran, a promising RNA interference therapy, is making waves by reducing TTR production and cardiac events for ATTR amyloidosis patients. These breakthroughs are saving lives—and driving innovation.

If you are an accredited investor who is passionate about saving lives while growing your investment portfolio, Evergrowth Biohealthcare Capital can be a good fit for you.

#Biotech #cardiacamyloidosis #cardiac #hearthealth #heartdisease #HealthcareInnovation #GeneTherapy #BiotechInvesting #MedicalBreakthroughs #HealthcareTech #Biohealthcare #MedicalResearch #InvestingInHealth #investing #investment #fund #hedgefund

▶ SCHEDULE A CALL WITH DR. TRAN:
https://calendly.com/drharveyt....ran/evergrowth-intro

▶ CONNECT WITH US:
Website: https://evergrowthinvest.com/
Email: info@evergrowthinvest.com
LinkedIn: https://www.linkedin.com/compa....ny/evergrowth-biohea
Phone: +1(704) 957-7746

▶ CONNECT WITH DR. HARVEY TRAN:
Twitter: https://twitter.com/DrTranBioSci
LinkedIn: https://www.linkedin.com/in/drharveytran/
Email: drharveytran@evergrowthinvest.com

Disclaimer: As a medical doctor/market expert, I’m not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I am also NOT responsible for the actions of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investment in stocks and options can result in a loss of capital. The information presented should NOT be construed as a recommendation to buy or sell any form of security. My articles and videos are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your actions. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized. That aside, what I shared with you is not professional medical advice. I simply share with you what I share with my own family to help get more out of your life.

Management of Newly Diagnosed AL Amyloidosis
Management of Newly Diagnosed AL Amyloidosis administrator 0 Views • 1 month ago

In this episode we discuss the management of newly diagnosed AL amyloidosis with Dr. Angela Dispenzieri from the Mayo Clinic.
Here are the key articles discussed:
1. Optimal use of tissue biopsy in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/28271734/

2. Mayo 2004 staging: https://pubmed.ncbi.nlm.nih.gov/15365071/

3. Mayo 2012 staging: https://www.ncbi.nlm.nih.gov/p....mc/articles/PMC36756

4. Renal staging: https://pubmed.ncbi.nlm.nih.gov/25115890/

5. Hematologic and cardiac response criteria in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/23091105/

6. ANDROMEDA Trial: Dara-VCD vs VCD in newly diagnosed AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/34192431/

7. How I Treat AL Amyloidosis: https://pubmed.ncbi.nlm.nih.gov/34517412/

8. Venetoclax in AL amyloidosis (largest retrospective study till date):
https://pubmed.ncbi.nlm.nih.gov/33431806/

Amyloidosis Pathogenesis | Introduction | Pathology V-Learning for Medical Students
Amyloidosis Pathogenesis | Introduction | Pathology V-Learning for Medical Students administrator 1 Views • 1 month ago

Medical topics are sometimes difficult to understand. Welcome to sqadia.com we are here to guide you through the sea. Today, our discussion will revolve around Amyloidosis.

▬ 📌 Amyloidosis
Amyloidosis can be referred to as a disease characterized by tissue damage due to extracellular protein deposits or amyloids that interfere with normal functioning.

👉 Morphology of Amyloidosis
Protein deposits or amyloids can have two stable shapes:
🟡 Native form
🟡 Beta sheets (which then clump together to form amyloid fibrils).

We will discuss all these reasons ahead so stick around.

▬ 📌 Pathogenesis of Amyloidosis
If we talk about Amyloidosis pathophysiology, Misfolded proteins are cleaved by proteases which sometimes cannot handle the protein burden and misfolded proteins pile up or in some cases, proteins opt such a morphology that is resistant to breakage.

▬ 📌 Types of Amyloidosis
Let’s hover over the types and their mechanisms. Types include:
🔵 AL or primary amyloidosis
🔵 AA or secondary amyloidosis
🔵 Systemic amyloidosis
🔵 Localized amyloidosis

Watch the video for more details.

▬ 📌 Signs and Symptoms of Amyloidosis
Let’s explore about the signs and symptoms which encompass:
⚫️ Kidney (Swelling in face, ankle, and legs)
⚫️ Intestine (Malabsorption and weight loss)
⚫️ Heart (Palpitations)
⚫️ Brain (Memory loss)

▬ 📌 Diagnosis of Amyloidosis
Let us have a glance over the diagnosis of Amyloidosis. Diagnostic tools are:
🟢 Congo Red Stain
🟢 Polarized Light
🟢 Biopsy

▬ 📌 Treatment of Amyloidosis
Treatment of Amyloidosis involves,
🔴 Chemotherapy
🔴 Cardiac Care
🔴 Organ Transplantation

So that was all about an overview of our video on Amyloidosis pathogenesis!

▬ 🎬 5500+ sqadia.com Medical Videos ▬▬▬▬▬▬▬▬▬▬
👩🏻‍⚕️ Accessible Medical Student Education 24/7/365
💡 Simplifying Medical Learning
💪 Study Hard, Dream Big, Achieve More
Expert Insights Into Amyloidosis: Cardiac Amyloidosis - AL and ATTR are Two Different Conditions
Expert Insights Into Amyloidosis: Cardiac Amyloidosis - AL and ATTR are Two Different Conditions administrator 0 Views • 1 month ago

Dr. Mazen Hanna, cardiologist at the Cleveland Clinic and co-director of the Amyloid Program, explains how cardiac amyloidosis can originate from two very different types of amyloidosis: AL or ATTR. Dr. Hanna illustrates how physicians can identify cardiac amyloidosis and look to different diagnostic work-ups to understand whether the issues are due to AL or ATTR amyloidosis. These two conditions are treated differently and have different prognoses, emphasizing the importance of understanding the type of amyloidosis involved.
When the Doctor Becomes an Amyloidosis Patient
When the Doctor Becomes an Amyloidosis Patient administrator 0 Views • 1 month ago

Send us a text (https://www.buzzsprout.com/twi....lio/text_messages/23


What if you are a doctor and diagnosed with amyloidosis, and now you’re a patient? In this episode we’ll be talking with Dr. Charles Schulman, a general cardiologist. He was on the staff at Beth Israel Deaconess Medical Center for over 53 years, until he retired in early 2024. Back in 2020 he was diagnosed with Wild-Type Transthyretin Amyloidosis with cardiomyopathy – or ATTRwt-CM. It’s an interesting situation to be in, with lots of questions to understand how being a doctor impacts your experience as a patient and vice versa. For an overview of amyloidosis, please see episode 2 (for clinicians) or episode 3 (for patients).

Neurology Quiz #89 Neuromuscular Amyloidosis (Part 2 of 2 - investigation and treatment)
Neurology Quiz #89 Neuromuscular Amyloidosis (Part 2 of 2 - investigation and treatment) administrator 0 Views • 1 month ago

Autonomic function tests
Sural nerve biopsy
Inotersen
Patisiran
Tafamidis
Diflunisal
Overview of Amyloidosis for Patients
Overview of Amyloidosis for Patients administrator 0 Views • 1 month ago

Send us a text (https://www.buzzsprout.com/twi....lio/text_messages/23


This episode of All Things Amyloid is an adaptation of Amyloidosis Support Groups’ patient education video narrated by Michael York. You’ll hear a brief yet comprehensive overview of amyloidosis designed specifically for patients. It discusses what amyloidosis is, the wide range of symptoms, and which organs are typically involved. It focuses on the most common types, AL (light chain) and TTR (transthyretin), and summarizes the kinds of treatments that are currently available. The video can be found on AmyloidAware.com (http://amyloidaware.com/) .

Expert Insights Into Amyloidosis: Do You Need a Heart Biopsy to Diagnose Cardiac Amyloidosis?
Expert Insights Into Amyloidosis: Do You Need a Heart Biopsy to Diagnose Cardiac Amyloidosis? administrator 1 Views • 1 month ago

Dr. Ahmad Masri, Director of the Cardiac Amyloidosis Program at Oregon Health & Science University (OHSU), reminds us about the traditional approach to diagnosis of cardiac amyloidosis. Unfortunately, this has not been enough. Thankfully, over the past decade that has all changed. He talks about OSHU’s approach to diagnosis today and what other data is used to arrive at a diagnosis of cardiac amyloidosis, offering four sample patient cases for insights.
ATTR Amyloidosis & the Gut: GI Symptoms & Treatments
ATTR Amyloidosis & the Gut: GI Symptoms & Treatments administrator 0 Views • 1 month ago

John O. Clarke, M.D.
Director, Esophageal Program
Clinical Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University, Stanford, CA

Presented at the 2023 Amyloidosis Support Groups ATTR/Hereditary Meeting, Saturday, October 28, 2023
Showing 27 out of 28